Koyfin Home > Directory > Health Care > Intercept Pharmaceuticals > EBITDA

Intercept Pharmaceuticals EBITDA Chart (ICPT)

Intercept Pharmaceuticals annual/quarterly EBITDA from 2011 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Intercept Pharmaceuticals EBITDA for the quarter ending June 06, 2020 was $-51m a -45.61% increase of 23m year over year
  • Intercept Pharmaceuticals EBITDA for the last 12 months ending June 06, 2020 was $-297m a -1.43% increase of 4m year over year
  • Intercept Pharmaceuticals Annual EBITDA for 2019 was $-309m a 9.02% decrease of -28m from 2018
  • Intercept Pharmaceuticals Annual EBITDA for 2018 was $-281m a -15.98% increase of 45m from 2017
  • Intercept Pharmaceuticals Annual EBITDA for 2017 was $-326m a -8.56% increase of 28m from 2016
Other Income Statement Metrics:
  • Intercept Pharmaceuticals Net Income for the quarter ending December 12, 2018 was $-88m a 7.29% decrease of -6m year over year
  • Intercept Pharmaceuticals Total Revenue for the quarter ending September 09, 2018 was $47m a 19.79% increase of 9m year over year
View Chart On Koyfin

Quarterly ICPT EBITDA Data

06/2020$-51m
03/2020$-83m
12/2019$-88m
09/2019$-75m
06/2019$-63m
03/2019$-83m
12/2018$-81m
09/2018$-57m
06/2018$-69m
03/2018$-74m

Annual ICPT EBITDA Data

2019$-309m
2018$-281m
2017$-326m
2016$-354m
2015$-227m
2014$-113m
2013$-39m
2012$-19m
2011$-13m
2010$-16m